Keyphrases
Population Data
100%
Prediction Model
100%
National Cohort Study
100%
Metastatic Pancreatic Ductal Adenocarcinoma
100%
Overall Survival
80%
Treatment Strategy
60%
Patient Characteristics
60%
C-index
40%
Tumor Characteristics
40%
Treatment Characteristics
40%
Internal-external
40%
Tumor
20%
Clinical Practice
20%
Netherlands
20%
Confidence Interval
20%
Tumor Subtype
20%
Systemic Treatment
20%
Cancer Registry
20%
Population-based
20%
Peritoneal Metastasis
20%
Treatment Type
20%
Lactate Dehydrogenase
20%
Shared Decision Making
20%
Predictive Quality
20%
Carbohydrate Antigen 19-9 (CA19-9)
20%
Performance Status
20%
Patient Treatment
20%
Patient Tumor
20%
Laboratory Values
20%
Cox Regression Model
20%
Biliary Drainage
20%
Patient Communication
20%
Nodal Stage
20%
Liver Metastasis
20%
Best Supportive Care
20%
Clinical Tumor Stage
20%
Validation Scheme
20%
Electronic Decision Support Tool
20%
Gemcitabine Monotherapy
20%
Gemcitabine Plus Nab-paclitaxel
20%
FOLFIRINOX
20%
Albumin-bilirubin Grade
20%
Multivariate Cox Regression
20%
Number of Metastatic Sites
20%
Distant Lymph Node Metastases
20%
INIS
data
100%
patients
100%
pancreas
100%
populations
100%
metastases
100%
prediction
100%
adenocarcinomas
100%
tumors
50%
validation
37%
values
25%
performance
25%
calibration
25%
laboratories
12%
liver
12%
cancer
12%
tools
12%
sex
12%
netherlands
12%
lymph nodes
12%
decision making
12%
bilirubin
12%
multivariate analysis
12%
drainage
12%
lactate dehydrogenase
12%
albumins
12%
Medicine and Dentistry
Pancreas Adenocarcinoma
100%
Overall Survival
80%
Neoplasm
60%
Cross-Validation
40%
Gemcitabine
40%
Lymph Node Metastasis
20%
Lactate Dehydrogenase
20%
Clinician
20%
Monotherapy
20%
Proportional Hazards Model
20%
Liver Metastasis
20%
Cancer Staging
20%
Cancer Registry
20%
Systemic Therapy
20%
Shared Decision Making
20%
Bilirubin
20%
Supportive Care
20%
CA19-9
20%
Biliary Tract Drainage
20%
Peritoneum Metastasis
20%
Paclitaxel
20%
Nonoxinol 9
20%
Patient Communication
20%
Albumin
20%